Critics often claim that GLP-1 agonists (like semaglutide and tirzepatide) only provide temporary weight loss, arguing that patients regain weight after stopping the medication.

Explore how the FDA ruling on compounded GLP-1 drugs like semaglutide affects accessibility, insurance coverage, and what you can do next.

Weight loss has entered a new era with the rise of GLP-1-based peptides like semaglutide and tirzepatide.